Plain-English translation of NCT07161414 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new cancer medication called rilvegostomig that is given as an injection under the skin instead of through an IV. Researchers want to find the right dose of this medication and confirm it works safely in adults whose cancer has already been treated with standard therapies. The study has two parts: first, they will find the best dose, and then they will confirm that dose is safe and effective.
Currently, this medication is only available as an IV infusion, which requires visits to a clinic or hospital. This trial is exploring whether giving the medication as a simple injection under the skin could be easier and more convenient for patients, while still delivering the same benefits.
You likely qualify if…
You likely don't qualify if…
In Part 1, you will first receive one dose of the medication through an IV, then receive subsequent doses as injections under the skin combined with an enzyme that helps the medication absorb better. In Part 2, you will continue receiving the medication as injections under the skin. Throughout the study, you will have regular visits for blood tests, physical exams, and assessments to monitor how the medication is working and any side effects you may experience.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States
South Korea